SHENZHEN, China, Aug. 29, 2024 /CNW/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company"), which continues to build on its strengths in the global healthcare sector, has announced that it has commenced a comprehensive financial and legal due diligence on Bowen Therapeutics Inc ("Bowen Therapeutics"), which it intends to acquire. The move marks an important step in UTime's expansion of its presence in the field of innovative medical products, with the aim of strengthening its market position and advancing the future of medical technology.
Read more at newswire.caUTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
